抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展

孙雪林; 郑丽; 李鸿升; 胡欣; 张亚同

doi:10.6039/j.issn.1001-0408.2024.04.23

您当前的位置：

首页 >

文章列表页 >

抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展

综述 | 更新时间：2024-02-23

- 抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展
- Research progress of chemotherapy-related diarrhea induced by molecularly targeted anti-tumor drugs
- 中国药房 2024年35卷第4期页码：506-512
- 作者机构：
  
  1.北京医院药学部/国家老年医学中心/中国医学科学院老年医学研究院，北京　100730
  2.中国航天科工集团七三一医院药学部，北京　100074
- 作者简介：
  
  副主任药师，博士研究生。研究方向：药物警戒、老年合理用药。E-mail：sxl1220@163.com
  主任药师。研究方向：老年药学、药物警戒和合理用药。E-mail：750826140@qq.com
- 基金信息：
  
  中央高水平医院临床科研业务费专项(BJ-2023-200);Δ 基金项目国家重点研发计划项目(2020YFC2009000;2020YFC2009001)
- DOI：10.6039/j.issn.1001-0408.2024.04.23
  中图分类号： R979.1;R442.2
- 纸质出版日期：2024-02-29，
  
  收稿日期：2023-08-29，
  
  修回日期：2024-01-24，
扫描看全文
孙雪林,郑丽,李鸿升等.抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展 ^Δ[J].中国药房,2024,35(04):506-512.

SUN Xuelin,ZHENG Li,LI Hongsheng,et al.Research progress of chemotherapy-related diarrhea induced by molecularly targeted anti-tumor drugs[J].ZHONGGUO YAOFANG,2024,35(04):506-512.
孙雪林,郑丽,李鸿升等.抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展 ^Δ[J].中国药房,2024,35(04):506-512. DOI： 10.6039/j.issn.1001-0408.2024.04.23.

SUN Xuelin,ZHENG Li,LI Hongsheng,et al.Research progress of chemotherapy-related diarrhea induced by molecularly targeted anti-tumor drugs[J].ZHONGGUO YAOFANG,2024,35(04):506-512. DOI： 10.6039/j.issn.1001-0408.2024.04.23.

摘要

化疗相关性腹泻（CRD）可导致治疗效果和患者依从性降低，影响肿瘤患者的长期治疗结局，甚至危及生命。除传统化疗药物外，许多分子靶向药物也可导致CRD，包括小分子表皮生长因子受体（EGFR）抑制剂、抗EGFR单克隆抗体、磷酸肌醇3-激酶抑制剂、血管内皮细胞生长因子受体小分子抑制剂、

BCR-ABL1

和KIT抑制剂、人表皮生长因子受体2靶点抑制剂、周期蛋白依赖性激酶抑制剂、抗体-药物偶联物等多种分子靶向药物。其发生机制可能与分子靶向治疗药物引起肠黏膜损伤或肠炎等有关，临床表现为大便频率增加和/或松散不成形，患者常伴有产气过多和/或肠绞痛。不同药物引起的CRD发生率不同，临床应重视病史采集和鉴别诊断，积极干预并进行动态评估，加强患者教育，以及时发现和预防肠毒性的发生。

Abstract

Diarrhea caused by chemotherapy is called chemotherapy-related diarrhea （CRD）. CRD can lead to reduced treatment effectiveness and compliance， affect the long-term outcome of tumor patients， and can be life-threatening in severe cases. In addition to conventional chemotherapy drugs， many molecularly targeted drugs are also associated with CRD， including small molecule epidermal growth factor receptor （EGFR） inhibitors， anti-EGFR monoclonal antibodies， phosphoinositide 3-kinase inhibitors， small molecule inhibitors of vascular endothelial growth factor receptor，

BCR-ABL1

and KIT inhibitors， human epidermal growth factor receptor 2 target inhibitors， cyclin-dependent protein kinase inhibitors， antibody-drug conjugates and other molecularly targeted drugs. The occurrence mechanism may be related to the intestinal mucosal injury or enteritis caused by molecularly targeted drugs. The clinical manifestations are increased stool frequency and/or loose imposition， and patients are often associated with excess hyperproduction and/or colic. The incidence of CRD varies with different drugs. Great importance should be attached to collecting medical history and differential diagnosis， actively intervening and conducting dynamic evaluation， strengthening patient education， and timely detecting and preventing the occurrence of intestinal toxicity.

关键词

化疗相关性腹泻肿瘤靶向治疗肠毒性不良反应

Keywords

tumortargeted therapyintestinal toxicityadverse drug reactions

references

LIU C，AMIN R，SHATILA M，et al. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects[J]. J Cancer Res Clin Oncol，2023，149（7）：3965-3976.

CIORBA M A. Advances in understanding and improving gastrointestinal symptoms during supportive and palliative care：a decade of progress[J]. Curr Opin Support Palliat Care，2016，10（2）：149-151.

THORPE D，STRINGER A，BUTLER R. Chemotherapy-induced mucositis：the role of mucin secretion and regulation，and the enteric nervous system[J]. Neurotoxicology，2013，38：101-105.

BOERS-SONDEREN M J，MULDER S F，NAGTEGAAL I D，et al. Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors：is the cause in the mucosa? [J]. Acta Oncol，2016，55（4）：444-448.

COHEN J V，DOUGAN M，ZUBIRI L，et al. Liver biopsy findings in patients on immune checkpoint inhibitors[J]. Mod Pathol，2021，34（2）：426-437.

ALESSANDRINO F，TIRUMANI S H，KRAJEWSKI K M，et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre：chemotherapy，haematopoietic stem cell transplantation，molecular targeted therapies，and immune checkpoint inhibitors[J]. Clin Radiol，2017，72（7）：521-533.

TOUYZ R M，HERRMANN S M S，HERRMANN J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events[J]. J Am Soc Hypertens，2018，12（6）：409-425.

TANG T L，ABU-SBEIH H，MA W J，et al. Gastrointestinal injury related to antiangiogenesis cancer therapy[J]. Clin Colorectal Cancer，2020，19（3）：e117-e123.

MOK T S，WU Y L，AHN M J，et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med，2017，376（7）：629-640.

KUDERER N M，DESAI A，LUSTBERG M B，et al. Mitigating acute chemotherapy-associated adverse events in patients with cancer[J]. Nat Rev Clin Oncol，2022，19（11）：681-697.

LINDNER A U，RESLER A J，CARBERRY S，et al. Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea[J]. J Mol Med，2020，98（1）：149-159.

YOKOTA T，UENO T，SOGA Y，et al. J-SUPPORT research policy for oral mucositis associated with cancer treatment[J]. Cancer Med，2022，11（24）：4816-4829.

KREIS W，PETRYLAK D，SAVARESE D，et al. Colitis and docetaxel-based chemotherapy[J]. Lancet，2000，355（9221）：2164.

GHIRINGHELLI F，VINCENT J，BELTJENS F，et al. Fluorouracil，leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients[J]. Invest New Drugs，2015，33（6）：1263-1266.

SORIA J C，OHE Y，VANSTEENKISTE J，et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med，2018，378（2）：113-125.

WU Y L，CHENG Y，ZHOU X D，et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer（ARCHER 1050）：a randomised，open-label，phase 3 trial[J]. Lancet Oncol，2017，18（11）：1454-1466.

GOLDBERG S B，REDMAN M W，LILENBAUM R，et al. Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer：final results from SWOG S1403[J]. J Clin Oncol，2020，38（34）：4076-4085.

VAN CUTSEM E，PEETERS M，SIENA S，et al. Open-label phase Ⅲ trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer[J]. J Clin Oncol，2007，25（13）：1658-1664.

TANIGUCHI H，YAMANAKA T，SAKAI D，et al. Efficacy of panitumumab and cetuximab in patients with colorectal cancer previously treated with bevacizumab：a combined analysis of individual patient data from ASPECCT and WJOG6510G[J]. Cancers，2020，12（7）：1715.

GOPAL A K，KAHL B S，DE VOS S，et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma[J]. N Engl J Med，2014，370（11）：1008-1018.

FLINN I W，O’BRIEN S，KAHL B，et al. Duvelisib，a novel oral dual inhibitor of PI3K-δ，γ，is clinically active in advanced hematologic malignancies[J]. Blood，2018，131（8）：877-887.

ANDRÉ F，CIRUELOS E，RUBOVSZKY G，et al. Alpelisib for PIK3CA-mutated，hormone receptor-positive advanced breast cancer[J]. N Engl J Med，2019，380（20）：1929-1940.

BRUIX J，QIN S K，MERLE P，et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment（RESORCE）：a randomised，double-blind，placebo-controlled，phase 3 trial[J]. Lancet，2017，389（10064）：56-66.

ABOU-ALFA G K，MEYER T，CHENG A L，et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med，2018，379（1）：54-63.

SCHLUMBERGER M，TAHARA M，WIRTH L J，et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med，2015，372（7）：621-630.

SMITH D C，SMITH M R，SWEENEY C，et al. Cabozantinib in patients with advanced prostate cancer：results of a phase Ⅱ randomized discontinuation trial[J]. J Clin Oncol，2013，31（4）：412-419.

KEUTGEN X M，ORNELL K J，VOGLE A，et al. Sunitinib-loaded chondroitin sulfate hydrogels as a novel drug-delivery mechanism for the treatment of pancreatic neuroendocrine tumors[J]. Ann Surg Oncol，2021，28（13）：8532-8543.

CASTAGNETTI F，RAIMONDO F D，VIVO A D，et al. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line[J]. Am J Hematol，2017，92（1）：82-87.

NISHIWAKI S，MAEDA M，YAMADA M，et al. Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients[J]. Blood，2017，129（1）：126-128.

JIMÉNEZ BELTRÁN V，BERMÚDEZ ALARCÓN A，CASTAÑO FERNÁNDEZ O. Dasatinib-induced colitis：discovering the side effects of immunotherapy[J]. Rev Esp Enferm Dig，2020，112（8）：663-664.

ATALLAH E，SCHIFFER C A，RADICH J P，et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia：a nonrandomized clinical trial[J]. JAMA Oncol，2021，7（1）：42-50.

BLAY J Y，SERRANO C，HEINRICH M C，et al. Ripretinib in patients with advanced gastrointestinal stromal tumours（INVICTUS）：a double-blind，randomised，placebo-controlled，phase 3 trial[J]. Lancet Oncol，2020，21（7）：923-934.

CORTES J E，GAMBACORTI-PASSERINI C，DEININGER M W，et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia：results from the randomized BFORE trial[J]. J Clin Oncol，2018，36（3）：231-237.

FONTANELLA C，LEDERER B，NEKLJUDOVA V，et al. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib[J]. J Clin Oncol，2014，32（30）：3458-3459.

CORTÉS J，FUMOLEAU P，BIANCHI G V，et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab：activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol，2012，30（14）：1594-1600.

MARTIN M，HOLMES F A，EJLERTSEN B，et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer（ExteNET）：5-year analysis of a randomised，double-blind，placebo-controlled，phase 3 trial[J]. Lancet Oncol，2017，18（12）：1688-1700.

MURTHY R K，LOI S，OKINES A，et al. Tucatinib，trastuzumab，and capecitabine for HER2-positive metastatic breast cancer[J]. N Engl J Med，2020，382（7）：597-609.

GOETZ M P，TOI M，CAMPONE M，et al. MONARCH 3：abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol，2017，35（32）：3638-3646.

SLAMON D J，NEVEN P，CHIA S，et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer[J]. N Engl J Med，2020，382（6）：514-524.

FINN R S，MARTIN M，RUGO H S，et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med，2016，375（20）：1925-1936.

VERMA S，MILES D，GIANNI L，et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med，2012，367（19）：1783-1791.

MODI S N，SAURA C，YAMASHITA T，et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med，2020，382（7）：610-621.

BARDIA A，MAYER I A，VAHDAT L T，et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med，2019，380（8）：741-751.

LI Z，XU H，YU L，et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy[J]. Clin Transl Med，2022，12（7）：e970.

UNVERZAGT S，MOLDENHAUER I，NOTHACKER M，et al. Immunotherapy for metastatic renal cell carcinoma[J]. Cochrane Database Syst Rev，2017，5（5）：CD011673.

JERUSALEM G，DE BOER R H，HURVITZ S，et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive，HER2-negative advanced breast cancer：the BOLERO-6 randomized clinical trial[J]. JAMA Oncol，2018，4（10）：1367-1374.

KHOZIN S，BLUMENTHAL G M，ZHANG L J，et al. FDA approval：ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer[J]. Clin Cancer Res，2015，21（11）：2436-2439.

KIM D W，MEHRA R，TAN D S W，et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer（ASCEND-1）：updated results from the multicentre，open-label，phase 1 trial[J]. Lancet Oncol，2016，17（4）：452-463.

PETERS S，CAMIDGE D R，SHAW A T，et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med，2017，377（9）：829-838.

BRONTE E，BRONTE G，NOVO G，et al. Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors[J]. Pharmacol Ther，2018，192：65-73.

BURGER J A，TEDESCHI A，BARR P M，et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med，2015，373（25）：2425-2437.

SHARMAN J P，EGYED M，JURCZAK W，et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia（ELEVATE TN）：a randomised，controlled，phase 3 trial[J]. Lancet，2020，395（10232）：1278-1291.

GOLAN T，HAMMEL P，RENI M，et al. Maintenance olaparib for germline BRCA-mutated metastatic pancrea-tic cancer[J]. N Engl J Med，2019，381（4）：317-327.

GONZÁLEZ-MARTÍN A，POTHURI B，VERGOTE I，et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med，2019，381（25）：2391-2402.

SCHNEIDER B J，NAIDOO J，SANTOMASSO B D，et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy：ASCO guideline update[J]. J Clin Oncol，2021，39（36）：4073-4126.

GARUTTI M，NOTO C，PASTÒ B，et al. Nutritional ma-nagement of oncological symptoms：a comprehensive review[J]. Nutrients，2023，15（24）：5068.

FRANCISCO D M A，ZHANG L L，JIANG Y，et al. Risk factors associated with severe Clostridioides difficile infection in patients with cancer[J]. Infect Dis Ther，2023，12（1）：209-225.

HUANG L，YE X H，WU F Q，et al. Study of prevalence and risk factors of chemotherapy-induced mucositis in ga-strointestinal cancer using machine learning models[J]. Front Oncol，2023，13：1138992.

ANDREYEV J，ROSS P，DONNELLAN C，et al. Gui-dance on the management of diarrhoea during cancer chemotherapy[J]. Lancet Oncol，2014，15（10）：e447-e460.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

奥马珠单抗治疗儿童过敏性疾病的安全性分析

不同肠内营养制剂用于重症急性胰腺炎的疗效及胃肠道耐受性研究

替加环素致严重肾功能不全患者凝血功能异常的回顾性分析

阿片受体激动-拮抗剂的镇痛作用及不良反应研究进展

重庆市2015－2022年药物过敏性休克救治使用肾上腺素情况的回顾性研究